HiLung
HiLung Inc. is a biotechnology company specializing in respiratory diseases, leveraging human iPS cell differentiation technology to mass-produce functional human respiratory epithelial cells. Their innovative platform combines lung stem cell biology with AI and device-based analysis to efficiently identify highly effective drug candidates in vitro, accelerating drug discovery and development for respiratory diseases including rare conditions like cystic fibrosis and idiopathic pulmonary fibrosis. They also develop regenerative medicine therapies using high-function cells for lung regeneration. The company operates a drug discovery platform and provides services including iPS cell-derived respiratory cell assays and differentiation induction. HiLung is positioned as a pioneering iPS cell-based respiratory drug discovery venture with a mission to innovate treatments and improve patient outcomes globally.
HiLung
HiLung Inc. is a biotechnology company specializing in respiratory diseases, leveraging human iPS cell differentiation technology to mass-produce functional human respiratory epithelial cells. Their innovative platform combines lung stem cell biology with AI and device-based analysis to efficiently identify highly effective drug candidates in vitro, accelerating drug discovery and development for respiratory diseases including rare conditions like cystic fibrosis and idiopathic pulmonary fibrosis. They also develop regenerative medicine therapies using high-function cells for lung regeneration. The company operates a drug discovery platform and provides services including iPS cell-derived respiratory cell assays and differentiation induction. HiLung is positioned as a pioneering iPS cell-based respiratory drug discovery venture with a mission to innovate treatments and improve patient outcomes globally.